New treatment options for heparin-induced thrombocytopenia.
Journal Article (Review)
A rapidly acting anticoagulant that can either inhibit thrombin generation or inhibit thrombin itself is the optimum therapy for acute thrombosis associated with heparin-induced thrombocytopenia (HIT). In this review, the newer treatment approaches that fulfill this requirement are discussed. These newer treatments include hirudin and argatroban, direct thrombin inhibitors, and danaparoid, which inhibits thrombin generation. Preliminary outcome results from the extensive compassionate-use program for danaparoid in HIT and from a recently completed randomized clinical trial that compared danaparoid with dextran in patients with HIT are provided. Based on these data, danaparoid appears to be a useful and safe replacement for heparin in patients who develop HIT.
Full Text
Duke Authors
Cited Authors
- Ortel, TL; Chong, BH
Published Date
- October 1998
Published In
Volume / Issue
- 35 / 4 Suppl 5
Start / End Page
- 26 - 34
PubMed ID
- 9855181
Pubmed Central ID
- 9855181
International Standard Serial Number (ISSN)
- 0037-1963
Language
- eng
Conference Location
- United States